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ABSTRACT 
A survey on the presence of pharmaceuticals in urban wastewater of a Spanish 
Mediterranean area (Castellon province) was carried out. The scope of the study included a 
wide variety of pharmaceuticals belonging to different therapeutical classes. For this purpose, 
112 samples, including influent and effluent wastewater, from different conventional wastewater 
treatment plants were collected. Two monitoring programmes were carried out along several 
seasons. The first was in June 2008 and January 2009, and the second in April and October 
2009. During the first monitoring, the occurrence of 20 analytes in 84 urban wastewater 
samples (influent and effluent) was studied. The selection of these pharmaceuticals was mainly 
based on consumption. From these, 17 compounds were detected in the samples, with 
analgesics and anti-inflammatories, cholesterol lowering statin drugs and lipid regulators being 
the most frequently detected groups. 4-Aminoantipyrine, bezafibrate, diclofenac, gemfibrozil, 
ketoprofen, naproxen and venlafaxine were the compounds most frequently found. In the 
highlight of these results, the number of analytes was increased up to around 50. A lot of 
antibiotic compounds were added to the target list as they were considered “priority 
pharmaceuticals” due to their more potential hazardous effects in the aquatic environment. Data 
obtained during the second monitoring programme (spring and autumn) corroborated the results 
from the first one (summer and winter). Analgesics and anti-inflammatories, lipid regulators 
together with quinolone and macrolide antibiotics were the most abundant pharmaceuticals. 
Similar median concentrations were found over the year and seasonal variation was not clearly 
observed. The removal efficiency of pharmaceuticals in the wastewater treatment plants was 
roughly evaluated. Our results indicated that elimination of most of the selected compounds 
occurred during the treatment process of influent wastewater, although it was incomplete. 
Keywords 
Pharmaceuticals; Liquid chromatography-tandem mass spectrometry; Effluent and 
influent wastewater; Waste water treatment plant; Occurrence; Removal efficiency. 
 
 
 
1. Introduction 
Pharmaceutical consumption is continuously increasing around the word. Only in Spain, 
about 729 millions of prescriptions were sold in 2004. Six years later, the consumption 
increased around 30% reaching 958 millions prescriptions 
(http://www.msps.es/profesionales/farmacia/datos/home.htm). This has lead to an increasing 
concern regarding possible ecological risks coming from pharmaceuticals released into the 
environment. 
Pharmaceuticals are used extensively in human and veterinary medicine to prevent 
illness and also as growth promoters in livestock and fish farming as well as in agriculture. After 
administration, pharmaceuticals can be transformed in the human body into more polar and 
soluble forms as metabolites or as conjugates of glucuronic and sulphuric acid (Heberer, 2002; 
Nikolaou et al., 2007). Pharmaceuticals and their metabolites are readily excreted with urine 
and faeces and enter into urban wastewater treatment plants (WWTPs). Some of these 
compounds are eliminated by chemical or biological processes while others are degraded 
during sewage treatment processes or removed from the water phase by adsorption onto solid 
phase (e.g. sludge) (Jones et al., 2005). Data recently reported show that some 
pharmaceuticals are accumulated in sewage sludge. This indicates that even good removal 
rates obtained in aqueous phase (i.e. comparison of influent and effluent wastewater 
concentrations) do not imply degradation to the same extent. In general, the elimination of most 
of the substances is incomplete and improvements of the wastewater treatment and subsequent 
treatments of the produced sludge are required to prevent the introduction of these micro-
pollutants in the environment (Jelic et al., 2011). At present, urban wastewaters are considered 
the most important source of pharmaceutical compounds in the aquatic environment. WWTPs 
were designed to remove organic pollutants, mainly estimated as dissolved organic matter, 
solids and nutrients but not pharmaceutical compounds. Disposal of unused pharmaceuticals 
directly into domestic waste and application to livestock as veterinary drugs and feed additives 
can also contribute to their introduction in the environment (Heberer, 2002; Nikolaou et al., 
2007). 
Removal efficiencies in WWTPs depend on several factors such as compound physico-
chemical properties, the climate conditions (e.g. temperature and sunlight intensity), the type of 
treatment process employed, the operational conditions of the treatment process (temperature 
of operation, redox conditions, solids retention time and hydraulic retention time) as well as the 
age of the activated sludge used in the plant (Castiglioni et al., 2006; Suárez et al., 2008; Le-
Minh et al., 2010). Therefore, removal efficiencies can vary significantly from plant to plant and 
within a plant at different time periods (Vieno et al., 2007). 
WWTPs typically employ conventional sewage treatment consisting on primary 
sedimentation followed by secondary treatment and final sedimentation. Organic pollutants can 
be transformed from the aqueous phase by hydrolysis, biotransformation or sorption to primary 
and secondary sludges (Le-Minh et al., 2010). However, the removal efficiency is variable as it 
is highly affected by the compound affinity to remain in the aqueous phase of the treated 
effluent (hydrophilic pharmaceuticals) or to be adsorbed to sludge (hydrophobic chemicals). In 
contrast, tertiary treatment or advanced treatment processes such as membrane filtration, 
activated carbon or oxidative processes (chlorination, ozonation and ultraviolet irradiation) seem 
to be more efficient when they work under optimum conditions. Nevertheless, their use is not 
widespread due to their high cost in terms of energy consumption. 
Little is known about possible human and ecological adverse effects derived from the 
presence of pharmaceuticals in the aquatic environment. Although the concentration levels 
detected after wastewater treatment processes seem not to cause toxic effects on human 
health and in the aquatic environment, there is a big concern on the long-term exposure of 
aquatic organisms to pharmaceuticals. Antibiotics are of special interest because they can 
promote bacterial resistance in the environment due to continuous exposure (Kümmerer, 
2009a, 2009b; Zuccato et al., 2010). It is a problematic issue for flora and fauna as well as for 
humans, especially in those places where treated effluents are used to supplement drinking 
water supplies (Le-Minh et al., 2010). Consumption on antibiotics varies from country to country. 
Spain is one of the most consuming countries in terms of total amount. Broad spectrum 
antibiotics, which have the greatest impact on the development of resistance, are widely 
consumed according to the European Surveillance of Antimicrobial Consumption (ESAC) 
homepage (http://app.esac.ua.ac.be/public/index.php/ en_eu/antibiotic/ antibiotic-consumption). 
The aim of this paper is to investigate the occurrence and behavior of pharmaceuticals 
in wastewater treatment plants placed in the Castellon province (Spanish Mediterranean area) 
in order to have a realistic knowledge of the presence of pharmaceuticals in this region. A total 
of 112 samples (untreated and treated urban wastewater samples) from three WWTPs were 
analyzed by liquid chromatography coupled to tandem MS, along two monitoring programmes 
over the four seasons: summer (June), winter (January), spring (April), and autumn (October). 
Up to 47 pharmaceuticals were determined including a notable number of antibiotics. The 
occurrence and removal of these pharmaceuticals in different WWTPs and the effect of the 
seasonal variation on the elimination of pharmaceuticals was assessed. 
 
2. Experimental 
2.1. Reagents and chemicals 
Reference standards were purchased from Sigma–Aldrich (St Louis, MO, USA), LGC 
Promochem (London, UK), Toronto Research Chemicals (Ontario, Canada), Across Organics 
(Geel, Belgium), Bayer Hispania (Barcelona, Spain), Fort Dodge Veterinaria (Gerona, Spain), 
Vetoquinol Industrial (Madrid Spain) and Aventis Pharma (Madrid, Spain). 
Isotopically labeled compounds used were omeprazole-d3, acetaminophen-d4, 
diclofenac-d4, salicylic acid-d3 and ibuprofen-d3, from CDN Isotopes (Quebec, Canada); 
atorvastatin-d5, paroxetine hydrochloride-d4 and olanzapine-d3, from Toronto Research 
Chemicals (Toronto, Canada); sarafloxacin-d8 hydrochloride trihydrate, from Sigma–Aldrich; and 
sulfamethoxazole-13C6 and trimethoprim-13C3, from Isotope Cambridge Laboratories (Andover, 
MA, USA). 
HPLC-grade methanol (MeOH) and HPLC-grade acetonitrile (ACN) were purchased 
from Scharlab (Barcelona, Spain). HPLC-grade water was obtained from purification of 
demineralised water in a Milli-Q Gradient A10 (Millipore, Bedford, MA, USA). Formic acid 
(HCOOH, content >98%), ammonium acetate (NH4Ac, reagent grade) and sodium hydroxide 
(NaOH, >99%) were supplied by Scharlab (Barcelona, Spain). 
Standards were dissolved in MeOH, except macrolides, sulfonamides and lincosamides 
that were prepared in ACN. The addition of NaOH was necessary for the proper dissolution of 
acidic analytes like quinolones. A mix of all compounds was prepared in MeOH and 
subsequently diluted with water to obtain working standard solutions. A mix of isotopically 
labeled internal standards (ILISs) was also prepared in MeOH and used as surrogate. All 
standard solutions and ILIS mix were stored in amber glass bottles at −20 °C in a freezer. 
Cartridges used for SPE were Oasis HLB (60 mg) from Waters (Milford, MA, USA). 
 
2.2. Instrumentation 
Ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC) 
analysis was carried out using an Acquity UPLC system (Waters, Milford, MS, USA), equipped 
with a binary solvent pumping. In the first monitoring, chromatographic separation of the 20 
pharmaceuticals was achieved using an Acquity UPLC BEH column, 1.7 µm, 50 mm × 2.1 mm 
(i.d.) (Waters). Later, when the number of compounds increased up to 47, a longer column 
(Acquity UPLC HSS T3, 1.8 µm, 100 mm × 2.1 mm (i.d.)) was required for a satisfactory 
separation of all analytes but maintaining similar chromatographic runs. The LC system was 
interfaced to a TQD (triple quadrupole) mass spectrometer with an orthogonal electrospray 
ionization source Z-spray (Waters Corp.). MS/MS analysis was performed under selected 
reaction monitoring (SRM) mode, working in positive and negative ionization modes 
simultaneously. Chromatographic and mass spectrometry conditions can be found in detail in 
our previous papers (Gracia-Lor et al., 2010, 2011). 
 
2.3. Analytical procedure 
Water samples were extracted as described in Gracia-Lor et al. (2010, 2011).  Briefly, 
the procedure was as follows: 100 mL water sample (100 mL effluent wastewater (EWW) or 20 
mL influent wastewater (IWW) diluted with water to 100 mL) spiked with the ILIS mix working 
solution was passed through the Oasis HLB cartridge, previously conditioned. Analytes were 
eluted with 5 mL MeOH and the extract was evaporated and reconstructed with 1 mL MeOH–
water (10:90, v/v). Finally, 20 µL of the final extract were injected in the UHPLC–MS/MS 
system. Quantification was made using calibration standards prepared in solvent, based on 
relative responses analyte/ILIS or on absolute analyte responses, depending on whether ILIS 
was used for correction or not. All methods applied were previously validated (Gracia-Lor et al., 
2010, 2011). 
2.4. Sampling  
EWW and IWW samples were collected along 2008 and 2009. They were obtained from 
three WWTPs (Castellon de la Plana, Benicassim and Burriana) of the Castellon province 
(Spanish Mediterranean area). These WWTPs are designed to treat wastewaters (urban o 
mixed urban and industrial) operating with secondary treatment using conventional activated 
sludge. At present, the Castellon de la Plana WWTP has a tertiary treatment operating with 
sand filtration and ultraviolet irradiation, but it was not operating when the monitoring was 
carried out. Castellon de la Plana WWTP has a population equivalent of 265,000 inhabitants, 
while Benicassim and Burriana WWTPs serve to a population around 18,000 and 35,000 
inhabitants. For each plant, 24-h composite untreated (influent) and treated wastewater 
samples (effluent) were obtained. Samples were frozen and stored at −18 °C until analysis. 
Sampling was carried out in two campaigns. In the first monitoring, samples were 
collected along one complete week in June 2008 and in January 2009 and the occurrence of 20 
pharmaceuticals was investigated (Gracia-Lor et al., 2010). In the second monitoring, in the light 
of the results obtained, the number of investigated compounds was increased up to 47 in order 
to have a wider knowledge of the presence of pharmaceuticals in wastewaters. Most of 
pharmaceuticals added in the second monitoring corresponded to antibiotics. In this case, only 
EWW and IWW samples from the Castellon de la Plana WWTP (the main town of the Castellon 
province) were analyzed as no significant differences between the three studied WWTPs were 
observed and this treatment plant serves a larger population. 24-h Composite samples (IWW 
and EWW) were collected during one complete week in April 2009 and October 2009. 
 
3. Results and discussion 
3.1. First monitoring  
First of all, a group of 20 pharmaceuticals were selected including the most consumed 
active principles with medical prescription in Spain (Ministry of Health, 2008, 2009). Several 
compounds with low official sales volumes (in terms of medical prescription) but frequently 
detected in urban wastewater as reported by other authors (Ternes, 2001; Gros et al., 2006; 
Hernando et al., 2007; Pedrouzo et al., 2007) were also included (e.g. diclofenac, naproxen or 
bezafibrate). In addition, two metabolites were considered: salicylic acid, which is the main 
metabolite of acetylsalicylic acid, and 4-aminoantipyrine, which is a metabolite of dipyrone. 
These metabolites were selected because they had been frequently determined in the aquatic 
environment (surface water and wastewater) according to scientific literature (Ternes et al., 
2001; Heberer, 2002; Metcalfe et al., 2003; Wiegel et al., 2004). Thus, 20 pharmaceuticals for 
human use were selected (Table 1). Target analytes represented a broad range of chemicals 
classes including analgesic and anti-inflammatory, cholesterol lowering statin drugs, lipid 
regulators, antidepressants, anti-ulcer agents, psychiatric drugs, ansiolitics and cardiovasculars. 
In total, 84 wastewater samples were analyzed in this monitoring, and collected from 
three WWTPs of the Castellon province. Sample collection was performed in summer 2008 
(June) and winter 2009 (January). Table 1 shows the percentage of positive findings of the 
selected compounds, as well as median concentrations in IWW and EWW analyzed during this 
period. 
13 out of 20 compounds were detected in IWW. All 13 pharmaceuticals were identified 
in more than 95% of the samples, with the exception of salicylic acid and pravastatin, the latest 
only being present in 26% of IWW samples. Analgesics/anti-inflammatories and lipid regulators 
were the most commonly detected groups. Moreover, the highest values in this type of samples 
corresponded to salicylic acid, acetaminophen and ibuprofen (these three compounds belong to 
the anti-inflammatory therapeutic group) with maximum levels of 277, 201 and 40 µg L−1, and 
median concentration of 35.1, 44.8 and 12.4 µg L−1, respectively. Quantification of the samples 
with high analyte levels (typically above 100 µg L−1) required an additional analysis with 
previous dilution of the sample before the SPE step. 
When comparing the percentage of positive findings in IWW collected in summer and in 
winter, no relevant differences were found. However, when comparing the maximum levels 
found, higher concentrations were observed for some compounds in the winter samples. For 
example, in the case of acetaminophen, salicylic acid and ibuprofen, maximum concentrations 
increased from 84 to 201 µg L−1, from 47 to 277 µg L−1, and from 20 to 40 µg L−1, respectively. 
For the rest of compounds, no relevant variations in concentrations were observed. 
 
 
 
 
 
Ta
bl
e 
1 
S
um
m
ar
y 
of
 th
e 
re
su
lts
 o
bt
ai
ne
d 
in
 th
e 
fir
st
 m
on
ito
rin
g 
pr
og
ra
m
m
e 
of
 2
0 
ph
ar
m
ac
eu
tic
al
s 
(J
un
e 
20
08
 a
nd
 J
an
ua
ry
 2
00
9)
.
Th
er
ap
eu
tic
 g
ro
up
A
ce
ta
m
in
op
he
n
A
na
lg
es
ic
s 
an
d 
10
0
44
.8
 
1.
13
-2
01
0.
11
0
n.
d.
n.
d.
0.
09
4-
A
m
in
oa
nt
ip
yr
in
e
an
ti-
in
fla
m
at
or
ie
s
10
0
2.
26
 
0.
53
-6
.4
5
0.
03
10
0
0.
69
 
0.
42
-1
.6
8
0.
04
D
ic
lo
fe
na
c
10
0
0.
56
 
0.
26
-1
.4
9
0.
14
10
0
0.
33
 
0.
06
-0
.7
4
0.
05
Ib
up
ro
fe
n
98
12
.4
 
2.
28
-3
9.
8
0.
64
33
<L
O
Q
<L
O
Q
0.
25
K
et
op
ro
fe
n
10
0
0.
48
 
<L
O
Q
-1
.1
7
0.
11
10
0
0.
30
0.
15
-0
.6
2
0.
07
N
ap
ro
xe
n
10
0
1.
55
0.
27
-3
.5
8
0.
05
10
0
0.
17
<L
O
Q
-0
.7
2
0.
03
S
al
ic
yl
ic
 a
ci
d
76
35
.1
 
3.
10
-2
77
0.
97
26
<L
O
Q
<L
O
Q
-2
36
0.
43
A
to
rv
as
ta
tin
10
0
0.
11
<L
O
Q
-0
.4
5
0.
03
76
0.
02
0.
01
-0
.1
6
0.
00
7
P
ra
va
st
at
in
26
0.
20
0.
14
-0
.2
4
0.
12
30
0.
10
 
0.
07
-0
.1
7
0.
02
B
ez
af
ib
ra
te
10
0
0.
16
 
0.
02
-0
.4
6
0.
02
10
0
0.
07
 
0.
02
-0
.3
9
0.
01
G
em
fib
ro
zi
l
10
0
1.
11
0.
16
-2
.1
2
0.
05
10
0
0.
54
 
0.
15
-1
.2
4
0.
02
P
ar
ox
et
in
e
0
n.
d.
n.
d.
0.
20
0
n.
d.
n.
d.
0.
04
V
en
la
fa
xi
ne
10
0
0.
17
 
0.
04
-0
.5
2
0.
01
10
0
0.
14
 
0.
06
-0
.3
0
0.
00
4
O
m
ep
ra
zo
le
0
n.
d.
n.
d.
0.
03
0
n.
d.
n.
d.
0.
01
P
an
to
pr
az
ol
e
0
n.
d.
n.
d.
0.
07
65
0.
13
 
0.
05
-0
.1
8
0.
03
O
la
nz
ap
in
e
0
n.
d.
n.
d.
0.
01
0
n.
d.
n.
d.
0.
01
R
is
pe
rid
on
e
0
n.
d.
n.
d.
0.
00
9
0
n.
d.
n.
d.
0.
00
6
A
lp
ra
zo
la
m
0
n.
d.
n.
d.
0.
03
38
<L
O
Q
<L
O
Q
0.
01
Lo
ra
ze
pa
m
0
n.
d.
n.
d.
0.
05
55
0.
04
 
0.
03
-0
.0
6
0.
03
E
na
la
pr
il
C
ar
di
ov
as
cu
la
r
96
0.
14
 
0.
02
-0
.2
9
0.
02
0
n.
d.
n.
d.
0.
00
7
n.
d.
 (n
ot
 d
et
ec
te
d)
a  D
at
a 
on
 L
O
Q
 ta
ke
n 
fro
m
 (G
ra
ci
a-
Lo
r e
t a
l.,
 2
01
0)
.
In
flu
en
t w
as
te
w
at
er
  (
n 
= 
42
)
E
ffl
ue
nt
 w
as
te
w
at
er
  (
n 
= 
42
)
A
ns
io
lit
ic
s
%
 P
os
iti
ve
 
fin
di
ng
s
LO
Q
   
  
(µ
g 
L-
1)
a
P
sy
ch
ia
tri
c 
dr
ug
s
C
ho
le
st
er
ol
 lo
w
er
in
g 
st
at
in
 d
ru
gs
 a
nd
 
lip
id
 re
gu
la
to
rs
A
nt
id
ep
re
ss
an
ts
A
nt
i-u
lc
er
 a
ge
nt
s
M
ed
ia
n 
co
nc
en
tra
tio
n 
(µ
g/
L)
 
M
in
im
um
-M
ax
im
um
 
le
ve
ls
 (µ
g/
L)
LO
Q
   
  
(µ
g 
L-
1)
a
%
 P
os
iti
ve
 
fin
di
ng
s
M
ed
ia
n 
co
nc
en
tra
tio
n 
(µ
g/
L)
 
M
in
im
um
-M
ax
im
um
 
le
ve
ls
 (µ
g/
L)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding EWW, up to 14 target compounds were detected. Analgesic and anti-
inflamatories were frequently found (the exception was acetaminophen, which was never 
detected in the EWW samples in contrast to IWW where it was present in the 100% of 
samples). Cholesterol lowering statin drugs and lipid regulators were also found in a high 
number of samples but, with the exception of gemfibrozil, their median concentrations were 
below 0.10 µg L−1. Other compounds frequently detected were venlafaxine, pantoprazole and 
lorazepam. 
The removal of pharmaceuticals during wastewater treatment was estimated from 
concentration data in IWW and EWW. Considering that pharmaceuticals have rather different 
physico-chemical characteristics, their removal during treatment is expected to be diverse. In 
the literature, the removal efficiency is generally computed as the percentage of reduction 
between the dissolved aqueous phase concentration of the contaminant in the influent and the 
dissolved aqueous phase concentration of the contaminant in the effluent. Except for a few 
studies, pharmaceutical concentrations in sludge or suspended solid are generally not 
considered nor measured, probably because of the difficulty to sample and to analyze such 
complex matrices (Miège et al., 2009). However, the screening of sewage sludge showed that 
these micro-pollutants are very present in this medium. This indicates that even good removal 
rates obtained in aqueous phase (i.e. comparison of influent and effluent wastewater 
concentrations) do not imply degradation to the same extent (Jelic et al., 2011). When 
comparing pharmaceutical concentrations in IWW and EWW, like in this work, lower levels in 
EWW would be interpreted as a removal of the compound in the WWTP. This fact might be due 
to different factors like chemical and physical transformations, biodegradation and sorption to 
the solid matter. Thus, the conversion of a given pharmaceutical to compounds other than the 
analyzed one would lead to lower pharmaceutical levels in EWW concluding that an “apparent” 
removal takes place. 
In this work, acetaminophen, enalapril and ibuprofen were completely removed during 
the treatment processes (present in 100% and 96% of IWW samples, and never detected in the 
EWW samples), while the antidepressant venlafaxine, lipid regulator compounds, as well as 
analgesic and anti-inflammatory pharmaceuticals (with the exception of acetaminophen and 
ibuprofen) were detected in all EWW samples, although at concentrations lower than in IWW. 
On the other hand, some pharmaceuticals were not detected in IWW but they were present in 
EWW. This behavior was observed for pantoprazole and for the ansiolitic compounds 
alprazolam and lorazepam. This is in agreement with previous studies where some compounds 
were reported to be more abundant in effluents than in influents (Lacey et al., 2008; Gros et al., 
2010; Jelic et al., 2011).  In the case of the ansiolitic compounds, they were detected at very low 
concentrations in EWW (around or below the LOQ level). Maybe they were also present in the 
IWW samples but could not be detected due to the lower sensitivity of the method in this type of 
waters. The higher complexity of the influents leads to strong matrix effects (commonly 
ionization suppression), which can hamper the detection of some analytes at very low levels. 
The absence of ansiolitic compounds in the IWW might be also due to the enzymatic cleavage 
of the compound glucuronides and other conjugated metabolites and the subsequent release of 
the parent compound during the treatment process (Vieno et al., 2007; Lacey et al., 2008; Gros 
et al., 2010). 
Predicting the removal efficiencies of compounds during treatment processes is quite 
difficult because they are significantly affected by the specific operating conditions of each 
WWTP. However, some information can be obtained from the data reported by others on the 
behavior of pharmaceuticals during the treatment processes. For instance, analgesics and anti-
inflammatory pharmaceuticals have been detected in the aquatic environment in a broad 
number of studies. Within this group, our data showed that acetaminophen was removed by the 
three WWTPs. For salicylic acid, an efficient removal was also obtained in contrast to 
diclofenac, ketoprofen and naproxen that seemed to persist to the water treatment, although 
their levels in EWW were lower than in IWW. This behavior is consistent with scientific literature 
(Heberer, 2002; Gros et al., 2010). 
In the case of lipid regulators and cholesterol lowering statin drugs, they showed a 
variety of removal rates between 30% and 100% which is in fairly good agreement with previous 
studies (Jelic et al., 2011). In our case, the highest levels and frequency of detection were found 
for lipid regulators, especially for gemfibrozil. 
Comparing the three studied WWTPs, no significant differences in terms of removal 
efficiencies were observed for the analyzed compounds. This is because they work at similar 
operational conditions. 
 
3.2. Second monitoring  
A notable number of compounds (around 30 antibiotics and a cholesterol lowering statin 
drug) were added to the target list of our previous method in order to have a more realistic 
knowledge of the presence of pharmaceuticals in the environment. Many antibiotics were 
included due to the special concern on their potential negative effects on the aquatic 
environment, whereas simvastatin, a cholesterol statin drug, was added to the list due to its 
increased consumption with medical prescription. 
As differences among the three WWTPs were hardly observed in the first survey, in the 
second monitoring only the Castellon de la Plana WWTP was monitored, in two different 
seasons: spring (April 2009) and autumn (October 2009). This treatment plant was selected 
because it serves the largest population of the Castellon province (Table 2). Moreover, data 
obtained in the first monitoring revealed that the samples from this treatment plant typically 
presented the highest pharmaceutical levels. In this second monitoring, 28 wastewater samples 
(14 IWW and 14 EWW) were collected and analyzed (Table 3), corresponding to one whole 
week of April 2009 and one whole week of October 2009. 
 
 
In IWW, for those 20 pharmaceuticals also analyzed in the first monitoring, no relevant 
differences were observed except for diclofenac, which showed a lower frequency of detection. 
Similarly to the previous study, the highest concentrations in IWW were found for 
acetaminophen (134 µg L−1), salicylic acid (64 µg L−1) and ibuprofen (19 µg L−1). As pointed out 
before, these compounds are frequently prescribed but they can also be acquired without 
medical prescription, the so-called “over the – counter” (OTC) drugs. 
In the case of antibiotics, it is difficult to establish a general trend for each group. As 
shown in Table 3, 9 out of 26 selected antibiotics were detected in the influent samples. Among 
them, seven compounds (ciprofloxacin, clarithromycin, norfloxacin, ofloxacin, pipemidic acid, 
sulfamethoxazole and trimethoprim) were detected in all the samples. On the contrary, 
lincomycin, which can be used in both human and veterinary medicine, and sulfathiazole were 
detected in around 20% of IWW. Except for ciprofloxacin, antibiotic median concentrations in 
IWW did not exceed 1 µg L−1. 
Regarding EWW, our data suggest that elimination of most of the compounds analyzed 
is incomplete. Again, we may distinguish different behaviors. First of all, there is a group of 
compounds that were fully eliminated in the treatment plant (i.e. acetaminophen, enalapril, 
ibuprofen, salicylic acid). These results are in agreement with those reported by other authors 
(Gros et al., 2010) and supported the behavior observed in the first monitoring, with slight 
differences observed for salicylic acid. On the other hand, there are several compounds partly 
removed by the treatment processes. For these compounds, concentrations after treatment 
were normally lower than in IWW, but they were still present in the EWW analyzed. This is the 
case of most lipid regulators and anti-inflammatory drugs. In some particular cases, e.g. 
gemfibrozil, concentrations were slightly higher in the effluent. Another group of 
pharmaceuticals included those compounds that showed poor or non elimination in the 
treatment plant, as some macrolide antibiotics, ansiolitics and the anti-ulcer agent pantoprazole, 
which presented even higher percentages of positive findings in EWW than in IWW. This fact 
has been previously reported in other studies (Göbel et al., 2007; Gros et al., 2010). As pointed 
out before, this phenomenon might be explained by the higher LOQs in IWW compared to 
EWW, or by the release of the parent compound from glucuronides or other conjugated 
Table 2 
Characteristics of the Castellon de la Plana treatment plant.
WWTP Population (he)
Type of 
treatment
Type of 
wastewater 
treated
Designed treatment 
capacity (m3d-1)
Average flow 
(m3/day)
Minimum flow 
estimated (L/s)
Maximum flow 
estimated (L/s) Sampling
Castellon de 
la Plana
265,000 Secondarya Urban and 
industrial
42,000 36,000 139.06 752.31 Time-proportional 
composite (every 
60 minutes)
a Secondary treatment was applied at the time of the monitoring was performed. At present, a tertiary treatment is applied.
metabolites during the treatment process. Finally, several target analytes were never found 
either in IWW or EWW. It was not expected for those compounds such as simvastatin, 
omeprazole or paroxetine that belong to the list of the most consumed pharmaceuticals in Spain 
with medical prescription. Their absence might be explained because their excretion was mainly 
as metabolites or due to the parent compound transformation/degradation in the sewer system. 
Thus, searching for metabolites and/or transformation products of these compounds seems 
necessary to evaluate their impact into the aquatic ecosystem. 
Concerning sulfonamide antibiotics, only sulfamethoxazole was detected in EWW. In 
fact, it was present in 100% EWW analyzed although at very low levels, below 0.06 µg L−1. 
Some contradiction exists about its removal (Le-Minh et al., 2010) as some studies have 
observed an effective removal (Choi et al., 2008) while others not (Brown et al., 2006). This fact 
might be explained by differences in operational conditions of each WWTP. 
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The presence of trimethoprim is usually related to the detection of sulfamethoxazole 
since these pharmaceuticals are often administered together. In agreement with other studies 
(Ternes, 2001; Gros et al., 2010; Jelic et al., 2011), the removal of trimethoprim during the 
wastewater treatment was incomplete. 
In the case of macrolide antibiotics, all compounds belonging to this therapeutic group 
were detected in EWW, except for tylosin which was never found. Among them, the percentage 
of positive findings and concentrations may differ due to their different consumption pattern. The 
incomplete removal of macrolide antibiotics by WWTP is in agreement to previous works (Clara 
et al., 2005; Göbel et al., 2007). In our study, erithromycin and roxithromycin were present in the 
effluent samples, but absent in the corresponding influent. Some authors suggest that this might 
be due to the release of these compounds from faeces during the biological treatment (Göbel et 
al., 2007). 
Regarding quinolone antibiotics, they have been frequently detected in wastewaters 
from several countries, especially norfloxacin and ciprofloxacin. In our case, 5 out of 12 
compounds that belong to this group were found in EWW (see Table 3). 
The results obtained in this monitoring work support the interest for including antibiotics 
when monitoring pharmaceuticals in wastewater, as they have been found rather frequently in 
the samples. 
In all samplings carried out, samples were collected during one complete week. In 
general, concentration of pharmaceuticals did not significantly change along the week. This 
indicates that the consumption of the studied compounds is quite constant over the week in 
contrast to illicit drugs, which consumption clearly increases during the weekends and in special 
events (Bijlsma et al., 2009). 
In this survey, a more complete seasonal variation analysis could be made for the 
Castellon de la Plana WWTP, which was the only one sampled in all monitoring programmes 
(four seasons, from summer 2008 to autumn 2009). Regarding the 20 most consumed 
pharmaceuticals, initially selected, they did not show big variations in median concentrations 
over the year (Fig. 1a and b). This is in accordance to their use, which is rather constant along 
the year. For a few compounds higher concentrations were found in winter for IWW 
(acetaminophen, salicylic acid, naproxen or diclofenac). These compounds are analgesic and 
anti-inflammatory pharmaceuticals, which are consumed along the whole year, but especially in 
winter. 
  
Figure 1. Median pharmaceutical concentration in the influent (a) and in the effluent (b) of the 
Castellon de la Plana WWTP monitored along four seasons. 
Regarding antibiotics, a comparison between spring and autumn concentrations was 
made, as they were only determined in these two seasons (Fig. 2a and b). We did not observe 
relevant differences, as the same compounds were detected in both seasons at similar median 
concentrations. However, it is noteworthy that antibiotic concentrations were notable lower than 
for the rest of pharmaceuticals, probably because they are less consumed. The only exception 
was ciprofloxacin.  
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Figure 2. Median antibiotics concentration in the influent (a) and in the effluent (b) of the 
Castellon de la Plana treatment plant monitored in spring and autumn 2009. 
The removal efficiency (RE) of the Castellon de la Plana WWTP is illustrated in Fig. 3. 
Those pharmaceuticals that were not detected in influent and in effluent wastewater samples 
(e.g. simvastatin, paroxetine, pefloxacin, etc.) have been omitted in this figure. RE values were 
calculated as the ratio between the median concentration levels of each pharmaceutical in 
influents and effluents. Data from samples collected along a whole week in April 2009 have 
been used in this figure. This WWTP seemed to have good removal efficiency for most 
analgesics/anti-inflammatories like acetaminophen, ibuprofen, naproxen or salicylic acid (RE 
around 100%). As regards the four cholesterol lowering statin drugs/lipid regulators detected in 
wastewater, two of them seemed to be efficiently removed (atorvastatin, pravastatin), while 
partial removal was suggested for bezafibrate (RE around 40%) and no removal was observed 
for gemfibrozil. The cardiovascular enalapril was also efficiently removed. 
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In relation to antibiotics, 6 out of 13 compounds detected in wastewater were rather 
efficiently removed in the WWTP, whereas ofloxacin and trimethoprim showed RE between 
20% and 40%. However, negative RE were observed for 5 antibiotics because these 
pharmaceuticals were not detected in IWW samples but were present in the corresponding 
EWW samples. In this case, it was not possible to calculate the RE actually, and a reference 
value (−100%) was given in order to show their behavior in the figure. The same situation was 
observed for three more compounds (pantoprazole, alprazolam and lorazepam) that were not 
found in IWW although they were detected in EWW (all compounds marked as (*) in Fig. 3). As 
previously stated, this situation might be due to the non-detection in IWW as a consequence of 
the higher complexity of this matrix, with typically higher matrix suppression, and the higher 
LOQs resulting in IWW. It must be taken into account that concentration levels found in EWW 
were normally low for all those compounds. Thus, they might be present at low levels in the 
IWW as well, and might not have been detected. Therefore, this assigned arbitrary value of -
100% for al these 8 compounds might be questioned. 
In the case of gemfibrozil and diclofenac, negative RE values were due to a slight 
increase of their concentration during the treatment process, i.e., they were detected at higher 
concentration levels in the effluent. 
 
 Figure 3. Removal efficiency of the Castellon de la Plana WWTP. (Data from April 2009). (1) 
Analgesics and anti-inflammatories, (2) cholesterol lowering statin drugs and lipid regulators, (3) 
antidepressants, (4) anti-ulcer agents, (5) ansiolitics, (6) cardiovasculars, and (7) antibiotics. 
 
4. Conclusions 
In this study, a monitoring of around 50 pharmaceuticals has been made in IWW and 
EWW from three different WWTPs. Up to 17 compounds were detected in both IWW and EWW 
indicating that conventional treatment processes do not completely remove these micro-
pollutants. Among them, analgesics and anti-inflamatories, lipid regulators as well as quinolone 
and macrolide antibiotics were the major groups found. 
Selected pharmaceuticals could be divided into four groups according to their behavior 
in WWTPs: a few compounds were completely removed during the treatment processes (e.g. 
acetaminophen, enalapril, ibuprofen); another group of analytes were not fully removed, 
although their concentrations after treatment were significantly lower than in influent (e.g. lipid 
regulators). A third group of compounds were not detected in IWW but were present in the 
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EWW samples (e.g. ansiolitics and macrolide antibiotics). Finally, some pharmaceuticals were 
never detected in either IWW or EWW (e.g. simvastatin, paroxetine, sulfamethazine). 
Searching for metabolites may offer valuable information (Tarcomnicu et al., 2011), 
especially for those analytes never found in wastewater despite they were frequently used. 
Future research will be directed towards the investigation of metabolites by using quadrupole 
time of flight (QTOF) mass spectrometry. In those particular cases where pharmaceuticals were 
not detected in IWW but detected in the corresponding EWW samples, QTOF would also be an 
ideal approach to identify glucuronide and conjugated metabolites, if present in IWW. Thus, the 
occurrence of metabolites and conjugated compounds could be studied by this technique. 
Seasonal variation in terms of median concentration values was not clearly observed in 
IWW and EWW. However, when comparing the maximum levels reached, higher concentrations 
were found in winter (January 2009), especially for analgesic and anti-inflamatory 
pharmaceuticals, possible due to a higher consumption during this period of the year to treat, for 
example, seasonal flu. 
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